We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.20 | 3.03% | 40.76 | 40.59 | 40.80 | 40.80 | 40.12 | 40.15 | 2,775,124 | 22:20:00 |
From Jul 2022 to Jul 2024
By Pierre Bertrand
Roche Holding AG said Monday that Phase 3 Graduate studies of gantenerumab, for treatment of early Alzheimer's disease, failed to meet its primary endpoints.
The Swiss pharma company said the drug failed to slow patients' clinical decline, adding that the drug's removal of beta-amyloid, a protein that builds up to make plaques in the brains of people with Alzheimer's disease, was lower than expected.
Nearly 2,000 people in 30 countries participated in the studies. Although patients treated with the drug showed a slowing of clinical decline in Graduate I and Graduate II tests by 8% and 6%, respectively, when compared with those given placebos, the results weren't statistically significant, Roche said.
The company said it would keep working on novel diagnostics and treatments for Alzheimer's and that it would present the data at the Clinical Trials on Alzheimer's Disease Conference on Nov. 30.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
November 14, 2022 02:25 ET (07:25 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
